Sign inJoin waitlistJoin the waitlist

Patrick Hagen

Associate Professor of Medicine · Loyola University Medical Center

Credentials: · · · ·

History

Loyola University Medical Center
Present

Hematology and Medical Oncology
Loyola University Chicago Stritch School of Medicine
2014–2017
Internal Medicine
University of Minnesota Medical School
2011–2014
ST GEORGE'S UNIV SCH OF MED, ST GEORGE'S, GRENADA
2007–2011

Research

High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions
Review · Blood Cancer Journal · 2022 · First of 3 authors · Corresponding · 83 citations
The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma
Review · Biology of Blood and Marrow Transplantation · 2019 · First of 2 authors · Corresponding · 27 citations
Differential Diagnosis of Isolated Myeloid Sarcoma: A Case Report and Review of the Literature
Case report · Hematology Reports · 2015 · First of 4 authors · Corresponding · 17 citations

Kevin Barton
6 papers
PS
Patrick Stiff
6 papers
Ameet Kini
4 papers
Anita D'Souza
4 papers
Nasheed Hossain
4 papers
Stephanie Berg
4 papers
FE
Fatema Esmail
3 papers · 2 as a fellow
Parameswaran Hari
3 papers
Benjamin Massat
2 papers · 2 as a fellow
Binod Dhakal
2 papers
Saad Usmani
2 papers
SS
Scott Smith
2 papers

Clinical trials

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Principal investigator · Recruiting · Phase 3
SWOG Cancer Research Network
2024–2030
5-day Defibrotide Treatment for Hepatic SOS/VOD
Principal investigator · Unknown · Phase 2
Loyola University
2021–2022
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Principal investigator · Terminated · Phase 2
Loyola University
2009–2017
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Site PI · Recruiting · Phase 3
Eastern Cooperative Oncology Group
2025–2075